Image
Press Release
October 21, 2025
SK Biopharmaceuticals launches AI digital health business with Eurofarma in Ontario
Source:
New joint venture lands at MaRS, driving neurological care innovation with Ontario’s AI and life sciences talent
TORONTO, Ontario, October 21, 2025 – SK Biopharmaceuticals, part of South Korean conglomerate SK Group, and Eurofarma, a Brazil-based multinational pharmaceutical company, are expanding their presence in North America with the launch of a new AI digital health joint venture, Mentis Care, in Toronto, Ontario.
Focused on developing AI-driven epilepsy management solutions, Mentis Care will combine electroencephalogram (EEG) monitoring technology with predictive algorithms to help patients anticipate and manage seizures more effectively. The technology analyzes neurological patterns in real time, identifying precursors to seizure events and providing patients with advance warning.
This 50:50 joint venture marks both SK Biopharmaceuticals’ and Eurofarma’s first digital health initiative in North America and their first Canadian business operation. It aims to address the unmet need for predictive and preventive tools that complement pharmaceutical treatment of epilepsy.
SK Biopharmaceuticals is expanding beyond pharmaceuticals into digital healthcare to open new possibilities in patient care. Through Mentis Care, we will advance toward patient-centered innovation by integrating AI and clinical data to improve epilepsy treatment.
Donghoon Lee
CEO of SK Biopharmaceuticals
For Eurofarma, the JV represents the future we envision for healthcare, combining digital technologies and medicines for a transformative and positive leap in patients’ lives. We are a reference in central nervous system treatments in Latin America, with a broad portfolio of medicines and close relationships with psychiatrists and neurologists. For some years now, we have added digital innovation investments to our R&D activities, and since 2022, we have maintained a small operation in North America. With this new partnership, we will strengthen these fronts in a single move.
Rodrigo Pereira
Director of Entrepreneurship and Digital at Eurofarma
Located at the MaRS Discovery District, Mentis Care’s Toronto R&D centre joins a thriving, talent-dense ecosystem anchored by the Vector Institute and a network of world-class universities and research hospitals that are driving the convergence of AI and life sciences innovation.
This investment builds on the long-standing partnership between Ontario and South Korean companies, which have made significant contributions across the province’s advanced manufacturing and clean technology sectors in recent years. The launch of Mentis Care represents a new milestone in this collaboration, extending joint innovation into the growing digital health space.
Ontario’s life sciences sector is a pillar of our economy, driven by world-class talent, cutting-edge research, and a thriving ecosystem that attracts global investment. We congratulate SK Biopharmaceuticals and Eurofarma on this partnership, and look forward to seeing Mentis Care leverage Ontario's expertise and sector strengths to deliver AI-driven healthcare breakthroughs and strengthen our province’s leadership in innovative healthcare technologies.
Hon. Vic Fedeli
Minister of Economic Development, Job Creation and Trade
Mentis Care plans to expand its local team and strengthen industry-academic collaborations, with the objective of transforming neurological care through AI to improve patient outcomes.
Mentis Care is an AI-driven digital health company with a mission to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring. By combining the innovation capabilities of our partners, SK Biopharmaceuticals and Eurofarma, we aim to establish a new standard in digital epilepsy management for patients worldwide.
Hassan Kotob
CEO of Mentis Care
Invest Ontario supported the expansion by connecting the company with key partners and programs, ensuring Mentis Care’s North American debut is set up for success.
We’re proud that SK Biopharmaceuticals and Eurofarma chose Ontario as the base for their next phase of growth. This expansion reflects the confidence international investors have in the Ontario life sciences community and aligns with our strategy to diversify and deepen partnerships that contribute to a more resilient economy.
Khawar Nasim
CEO of Invest Ontario
The decision by SK Biopharmaceuticals and Eurofarma to choose Toronto over other global cities is a powerful vote of confidence in our region’s competitiveness. Mentis Care joins a growing roster of global companies investing in AI-powered life sciences here, each reinforcing Toronto’s position as one of the world’s most dynamic innovation centres.
Stephen Lund
CEO of Toronto Global
Invest Ontario continues to partner with forward-looking companies to unlock new opportunities and accelerate their success, while creating meaningful jobs and strengthening the province’s economy for the future.
For more information about Invest Ontario, please visit www.investontario.ca.
About Invest Ontario
Invest Ontario is the dedicated agency for investment attraction in the province. We serve as global businesses’ partner and one-window access to Ontario, providing expertise and tailored services throughout their investment journey. With a focus on the advanced manufacturing, life sciences and technology sectors, we are committed to securing strategic investments that create jobs, generate returns to the province and drive Ontario’s long-term economic growth and global competitiveness.
About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd.
SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with eight compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content screening, computer-aided drug design, and combinatorial chemistry, the companies drive R&D efforts in biology/discovery, medicinal chemistry, pharmacology, and clinical development. For more information, visit www.SKLifeScienceInc.com.
SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea’s second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. SK companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME's 100 Most Influential Companies of 2023. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about SK Inc., visit https://sk-inc.com/en/main/mainpage.aspx. For more information about SK Biopharmaceuticals, visit www.skbp.com/eng.
About Eurofarma
Established in 1972, Eurofarma operates in the health industry, producing and selling products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as prescription, OTC and personal care, generics, hospital, oncology, and animal health, as well as providing production services to third parties. With a broad coverage of therapeutic classes, the portfolio comprises more than 2,000 products and 3,700 SKUs (presentations), serving the main medical specialties.
Leader in medical products prescriptions in Latin America, Eurofarma is present in 22 countries with the largest sales force in the region, with coverage of 100% of Latin America countries and operations in the USA and Africa. It has more than 12,600 employees and 11 factories, with total production around 700 million units in the last year. The company invested more than R$ 700 million in innovation and achieved total net revenue of R$ 11.1 billion. Over the last 15 years, Eurofarma has recorded average annual growth of 17%.
About Mentis Care
Mentis Care is an AI-driven digital health company transforming neurological care through the first predictive AI platform for brain health. The platform is designed to detect and forecast seizures and other neurological events in real time. By combining advanced machine learning with clinical expertise, Mentis Care aims to give patients and families greater safety, confidence, and peace of mind — while setting a new global standard in brain health and digital neuromonitoring.
Related sectors
Media Contacts
Sunny Ng
Senior Advisor, Corporate Communications, Invest Ontario
INVEST ONTARIO. HERE TO HELP.